Federal and State Agencies Advise You Get An Emergency Radio!
Picture This Very REAL Scenario: A shortage of fuel has closed your electric utility — or any one of several natural or man-made disasters has just devastated your town, power is out all over the city with no signs of being restored, floodwaters lap at your doorstep, and you and your family are completely cut off from all human contact . . .
Are You Prepared? How will you know if and when you need to evacuate? Is the water from your tap safe to drink? Which shelters are still taking families? Where do you go? What do you do?
Staying informed could be a matter of life and death.
That’s why federal and state agencies advise that every American home should have an emergency radio.
Be Prepared in Any Circumstance! If your electric power fails due to a massive health epidemic, storms, flash floods, hurricanes, earthquakes, tornadoes or even the ever-present threat of terrorism, you need an emergency radio that WORKS in a REAL emergency.
The Dynamo Emergency Multi-Band Radio is the device you can depend on.
This powerful radio lets you stay informed throughout any type of emergency. Most importantly, the Dynamo Emergency Multi-Band Radio includes:
Hand-crank generator
NOAA weather band, AM/FM
1.5” speaker
Telescope antenna
Wrist strap
USB output jack to charge cellphone or other device
Mini USB input jack with cord
This sturdy radio is a must-have in every home and makes a great gift for friends and family you want to keep safe!
The Dynamo Emergency Weather Band Radio retails at $29.95, but it’s yours for FREE with this special offer. Your family’s safety is worth it — don’t miss this offer!
To Read More Breaking Financial News go to Newsmax Money
This email is never sent unsolicited. You have received this Newsmax email because you subscribed to it or someone forwarded it to you. To opt out, see the links below.
Remove your email address from our list or modify your profile. We respect your right to privacy. View our policy.
This email was sent by: Newsmax.com 362 N. Haverhill Road West Palm Beach, FL 33415 USA
P.S. Now, she’s giving brand-new hope to cancer patients across America by sharing this message. Please don’t turn away… it may just save your life.
This ad is sent on behalf of NewMarket Health Publishing, LLC. P.O. Box 913, Frederick, MD 21705, USA.
This email is never sent unsolicited. You have received this Newsmax email because you subscribed to it or someone forwarded it to you. To opt out, see the links below.
Remove your email address from our list or modifyyour profile. We respect your right to privacy. Viewour policy.
This email was sent by: Newsmax.com 362 N. Haverhill Road West Palm Beach, FL 33415 USA
With a foreword by President Donald J. Trump, Sean Spicer delivers the definitive insider account of the most consequential administration in modern American history.
Why four years out of office made Trump’s return historic — and why these changes are built to last.ORDER ON AMAZON →
LIVE BOOK LAUNCH EVENT
Join Sean Spicer at the Trump Kennedy Center
A candid conversation with Sean Spicer and Larry O’Connor on the people, the policies, and the process behind President Trump’s second term.
This event and book launch are proudly sponsored by Townhall. One of the last events at the Trump Kennedy Center before its multi-year renovation closure.
“
If you want to understand the people, the policies, and the process of my second term in office, read this book.
— PRESIDENT DONALD J. TRUMP
FROM THE FOREWORD_______SUBSCRIPTION INFO_______
This email is never sent unsolicited. It was sent to you because you signed up to receive this newsletter on the Townhall Media network OR a friend forwarded it to you. We respect and value your time and privacy. If this newsletter no longer meets your needs we will be happy to remove your address immediately.
Or Send postal mail to: Townhall Daily Unsubscribe P.O. Box 9660, Arlington, VA 22219* Copyright Townhall and its Content Providers. All rights reserved.
William Randolph Hearst possessed a rare gift for transformation: A single newspaper became a media empire; a remote and windswept stretch of California coastline became one of the most storied estates in the country.
We are still running special subscription deals in light of the ongoing war with Iran. Take this opportunity to become an Epoch Times subscriber—at the best rates possible—while they’re still available!
The Epoch Times strives to fill the void at a time when partisan and biased reporting has become commonplace. As staunch believers in traditional journalism, we rigorously pursue facts and accuracy, leaving views strictly as opinions.
When you do choose to explore people’s perspectives, we guarantee you the freedom of thought. Too often, certain voices are suppressed or silenced—that’s never the case at The Epoch Times. Browsing through the commentaries, you will immediately recognize honest, refreshing, and at times courageous discussions on topics perhaps purposefully left out by others: HollywoodCan Still Make Great Movies; What I Sawat the White House Correspondents’ Dinner; A Former Anthropic Employee’s Last Warning
Can aging be treated like a disease? Could AI soon outperform medical specialists? And are peptides the next frontier in recovery and longevity? On “Vital Signs,” physician co-founder of the…
Our Good Evening newsletter helps you catch up on the big stories of the day followed by lifestyle and uplifting content. Manage your email preferences here or unsubscribe from Good Evening here.
GLP-1 seller Hims & Hers Health (NYSE: HIMS) has seen significant volatility in its stock price lately. Notably, despite a 41% single-day surge in early March, HIMS remains down nearly 10% in 2026. That sharp move followed an announcement that Hims and Novo Nordisk A/S (NYSE: NVO), the maker of Wegovy, were entering into a new collaboration.
Hims no longer needs to sell copycat versions of Novo’s weight-loss and diabetes drugs. Novo will allow Hims to sell branded versions of its Ozempic and Wegovy injectables, as well as the Wegovy pill. Novo also dropped its lawsuit against Hims. With Novo’s revenues moving in the wrong direction, Hims will act as a sales channel for the company.
Jensen Huang stood in Las Vegas and laid out Nvidia’s vision for building the world’s first trillion-dollar robot. But there’s one thing Nvidia can’t do alone.
A virtually unknown $7 company holds the technology Nvidia needs to make that vision a reality. Analyst Michael Robinson – who called Nvidia at $0.80 and Bitcoin at $300 – has identified this stock as his next potential winner, with nearly 20 prior calls returning 1,000% or more.Click here to learn which $7 stock Nvidia needs right now
However, Hims now faces competition from one of the largest consumer companies in the world: Amazon.com (NASDAQ: AMZN). In mid-April, Amazon added a weight management offering to its One Medical platform, and the announcement sent HIMS shares down 4%. Here’s how Amazon is positioning itself and what it could mean for Hims going forward.
Amazon Enters GLP-1 Game Through One Medical
Amazon says the Wegovy pill and the Foundayo GLP-1 pill will be available through One Medical. Foundayo is Eli Lilly and Company’s (NYSE: LLY) recently approved oral GLP-1, also known by the clinical name orforglipron. Cash-pay prices for the drugs start as low as $149 per month, which is in line with Hims’s pricing.
Amazon will also offer injectables for Wegovy and Zepbound, Lilly’s highly popular weight-loss drug. Cash-pay prices for these drugs start as low as $299 per month. While Zepbound prices are equal to Hims’s, Hims offers Wegovy injectables starting at $199.
Customers who use Hims or One Medical also must pay a membership fee. On this front, Amazon has a clear advantage. Amazon Prime members can add a One Medical membership for just $9 a month or $99 per year. That compares favorably with Hims, whose membership fee is $39 for the first month and $149 thereafter.
Furthermore, Amazon is offering same-day GLP-1 delivery to nearly 3,000 cities. It plans to expand that number to 4,500 cities by the end of 2026. Meanwhile, Hims notes delivery times of “as early as two days to a week.”
Amazon’s Lower Cost, Faster Delivery: A Problem for Hims
While Amazon may not necessarily be trying to undercut Hims on drug pricing, its lower membership fee and faster delivery times have clear advantages for consumers. For Amazon Prime members, an injectable Wegovy prescription would cost around $3,700 per year before taxes. On Hims, the total price would be above $4,000. For injectable Zepbound, the math is even worse: about $3,700 annually on One Medical, while exceeding $5,000 at Hims. At the same time, Amazon’s delivery speed could be much faster.
This poses a real competitive challenge for Hims. At the end of the day, the two companies are offering similar products and services at very different price points. Capital One estimates that there are approximately 180.1 million Amazon Prime members in the United States. Thus, for around half the U.S. population, it likely would not make economic sense to choose Hims over One Medical.
Additionally, an Amazon Prime membership costs just $139 per year. So if a consumer only wanted an Amazon Prime membership to access GLP-1s through One Medical, they could still pay less overall than they would with Hims.
However, whether consumers recognize this and decide to move to Amazon is far from certain. Hims has built a significant customer base of over 2.5 million subscribers and is growing fast. Sales hit $2.35 billion in 2025, up 59% year over year, but analysts expect growth to moderate sharply in 2026 to around 16%.
Hims isn’t new to competition, with many similar companies having entered its market over the past several years. However, none of those competitors has had the size and scope that Amazon does.
Hims Faces Greater Competition, Mixed Analyst Support
Overall, it will likely take several quarters to determine whether Amazon’s entry into this market significantly hurts Hims’s growth. Hims’s next earnings will cover Q1 2026, before One Medical’s GLP-1 launch. Given Amazon’s position as arguably the most powerful consumer company in the world, the long-term risks to Hims are very real.
Analysts continue to take a highly mixed view of Hims stock. MarketBeat currently tracks13 Hold ratings, four Buys, and one Sell.
The MarketBeat consensus price target near $32.50 implies about 10% upside in shares. However, targets updated after the company’s February earnings report are far less optimistic. They average approximately $26.30, a figure that implies around 10% downside.
Thank you for subscribing to MarketBeat!
MarketBeat empowers everyday investors to make better investment decisions by offering up-to-the-minute financial information and objective market analysis.
If you need help with your account, feel free to contact our South Dakota based support team at contact@marketbeat.com.
Flagstaff Beer Festival Saturday, June 20, 2026 Ft. Tuthill Fairgrounds 1–5 PM (VIP entry at noon)
June is shaping up to be hot and dry in the Valley, so come cool off with us at the Flagstaff Beer Festival and enjoy a beautiful Flagstaff summer afternoon.
Proceeds from the festival support STEM City Flagstaff and its work in our community.
News for you, Peter
Today’s game
Trending now1. 
